e-ISSN 2329-0072

Logo

Medical
MSM  BR

AmJCaseRep

Vancomycin Minimum Inhibitory Concentration (MIC) Creep and Its Effect on Mortality in Adult Cardiac Patients Who Developed Sepsis Caused by Staphylococcus Aureus and Coagulase-Negative Staphylococcus

Sanem Karadag Gecgel

Med Sci Tech 2017; 58:49-55

DOI: 10.12659/MST.905068

Available online: 2017-05-30

Published: 2017-05-30


BACKGROUND: The aim of our study was to determine the vancomycin MIC creep of the pathogens Staphylococcus aureus and coagulase-negative Staphylococcus (CNS) detected in blood cultures of patients with clinical signs of sepsis and to evaluate its effect on the mortality rate of patients.
MATERIAL AND METHODS: The patients with atherosclerotic heart disease, also diagnosed with sepsis, who were in the cardiology and cardiovascular surgery clinics and intensive care units between January 2011 and August 2015, were included in our study retrospectively, and 30-day mortality rates were evaluated.
RESULTS: Heteroresistant vancomycin-intermediate Staphylococcus aureus (hVISA) was detected in 57.5% of patients and vancomycin-intermediate Staphylococcus aureus (VISA) was detected in 2.7%. Vancomycin-intermediate CNS (VICNS) was detected 2.2%. According to vancomycin MIC values, S. aureus and S. epidermidis with vancomycin MIC ≥2 μg/mL were higher than vancomycin MIC <2 μg/mL (p=0.04, p=0.006), but S. hominis sups. hominis with vancomycin MIC <2 μg/mL was higher than vancomycin MIC ≥2 μg/mL (p<0.001). The mortality rate in patients with isolated S. aureus with vancomycin MIC=2 µg/mL was much more than with vancomycin MIC <2 µg/mL (p=0.050). The mortality rate in patients with isolated S. haemolyticus with vancomycin MIC ≥4 μg/mL was higher than vancomycin MICs (p=0.021).
CONCLUSIONS: We found higher mortality rates in patients with sepsis that have isolated hVISA. Determining the vancomycin MIC creep and the rates of hVISA strains in Staphylococci are important for planning treatment of patients with sepsis.

Keywords: Mortality, Staphylococcus aureus, Vancomycin



Back